Cancer Immunology and Immunotherapy

  • Glenn Dranoff

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 344)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Wolf H. Fridman, Jérome Galon, Marie-Caroline Dieu-Nosjean, Isabelle Cremer, Sylvain Fisson, Diane Damotte et al.
    Pages 1-24
  3. Heehyoung Lee, Sumanta Kumar Pal, Karen Reckamp, Robert A. Figlin, Hua Yu
    Pages 41-59
  4. Michele W. L. Teng, David S. Ritchie, Paul Neeson, Mark J. Smyth
    Pages 61-95
  5. Bent Rubin, Jean Edouard Gairin
    Pages 97-128
  6. Stephan A. Grupp, Carl H. June
    Pages 149-172
  7. Karolina Palucka, Hideki Ueno, Lee Roberts, Joseph Fay, Jacques Banchereau
    Pages 173-192
  8. Jinsheng Weng, Sattva S. Neelapu, Alison F. Woo, Larry W. Kwak
    Pages 193-210
  9. Francesca Avogadri, Jianda Yuan, Arvin Yang, David Schaer, Jedd D. Wolchok
    Pages 211-244
  10. Monica V. Goldberg, Charles G. Drake
    Pages 269-278
  11. Omar A. Ali, David J. Mooney
    Pages 279-297
  12. Jinsheng Weng, Sattva S. Neelapu, Alison F. Woo, Larry W. Kwak
    Pages 299-299
  13. Back Matter
    Pages 301-304

About this book


The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These “first-in-class” treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy.


dendritic cells immune infiltration regulatory T cells signal transducer and activator of transcription 3 (Stat3) tumor-immune interactions

Editors and affiliations

  • Glenn Dranoff
    • 1
  1. 1., Medical Oncology/Hematologic NeoplasialDana-Farber Cancer InstituteBostonUSA

Bibliographic information